Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corrona Psoriasis (PSO) Registry

Trial Profile

Corrona Psoriasis (PSO) Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Apremilast (Primary) ; Brodalumab (Primary) ; Ciclosporin (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Methotrexate (Primary) ; Risankizumab (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary)
  • Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Dec 2022 Results (n=113; CorEvitas Psoriasis Registry between 18 July 2017 and 10 March 2020) assessing the real-world effectiveness of guselkumab among patients living in the USA and Canada, published in the Dermatology and Therapy.
    • 14 Nov 2022 Results assessing the real world effectiveness of apremilast by disease activity presented at the ACR Convergence 2022.
    • 01 May 2022 Results reporting six month changes in disease status and patient-reported outcomes in patients with psoriasis initiating ixekizumab published in the Journal of Dermatological Treatment
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top